Conor: An Outsider Delivers Drug-Stents' Next Generation
Drug-eluting stents (DES), now approved in the US, will be the first blockbuster combination drug/device product to hit the market. First generation DES products use a stent design that remains basically unchanged from bare metal stents, bascially adding thin layers of drug and polymer coatings. Conor Medsystems is developing a stent that is specifically designed as a drug delivery vehicle, while still embodying the attributes required of a standard stent. Conor's stent is based on work done by an engineer with no expereince in the medical products industry, based on technology developed in other areas, bringing a fresh look to the future of combining drugs and stents that may extend to therapeutic applications beyond treating only cardiovascular disease.
By Stephen Levin
Innovation in medical devices is a tricky thing. While many companies like to describe their technologies as disruptive to underscore their purported dramatic clinical value, the truth is that most...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.